Print

VRC 607 HIV+

VRC 607: A Phase 1, Single Dose Study of the Safety and Virologic Effect of a Human MonoclonalAntibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity,Administered Intravenously to HIV-Infected Adults.

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) July 01, 2016
VRCHIVMAB080-00-AB Antibody VRC01LS
VRCHIVMAB080-00-AB Passive Immunization
USA 20
NCT02840474
https://clinicaltrials.gov/show/NCT02840474